An observational study in Obesity, Obesity, Morbid and Obesity, Primary, sponsored by Christopher C. Thompson, MD, MSc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Christopher C. Thompson, MD, MSc · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.
Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 44th largest by planned enrollment of the 63 observational ones that give a count, is one of 9 that started in 2023, is one of 63 observational ones, reaches primary completion later than 11 of the 34 other live ones, and was the 188th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18–90
The Cleveland Clinic · Sites in United States
Ages 18–70
University of Maryland, Baltimore · Sites in United States
Ages 18+ · Women only
University of Missouri-Columbia · Sites in United States
Ages 18+
Salvador Navarrete · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
213 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 11 · Phase 3 8 · Phase 4 13
First in 1980; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 39 across the 150 interventional studies, 50 across the 63 observational. Of the 147 that completed or were terminated, 56 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 213 have an industry lead sponsor. The 10 most frequent:
Christopher C. Thompson, MD, MSc is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Christopher C. Thompson, MD, MSc has 3 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
8 of the studies in Obesity, Morbid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06199154University of Maryland, BaltimoreInduction of Labor in Morbidly Obese Patients | 2026-12 |
| NCT05711758Christopher C. Thompson, MD, MScEfficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure | 2026-12 |
| NCT02602769Columbia UniversityWhole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome | 2026-12 |
| NCT05215886University of California, DavisCognitive Impairment, Obesity, and the Effects of Bariatric Surgery | 2026-12-31 |
| NCT03868592Mayo ClinicLong-term, Substantial Weight Loss and Insulin Regulation of Lipolysis | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 213 studies in Obesity, Morbid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.
Obesity, defined as body mass index (BMI) greater than 30 kg/m2 in adults, is affecting 30% of the global population and a significant healthcare burden. [1] Obesity has increased dramatically over the last few decades, with over 650 million adults, or 13% of the world's total adult population, diagnosed with the disease in 2016 - a figure that has nearly tripled since 1975.[1] In the U.S the obesity prevalence for U.S. adults increased from 14.1% to 26.7%, or an 89.9% increase between 1993 and 2008.[1,2,3] As a result, current and potential interventions, and treatment strategies to combat obesity have become more important.
The current treatment of obesity involves multiple strategies with combination of non-pharmacologic, pharmacologic, endoscopic, and surgical interventions. There are several FDA-approved pharmacotherapies for the treatment of obesity such as orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, and semaglutide. For adults with a body mass index (BMI) of 40 kg/m2 or 35 kg/m2 and obesity-related comorbidity, bariatric surgery can be offered. [4, 5] Endoscopic bariatric and metabolic therapies (EBMT) have emerged as an alternative treatment for patients with obesity with a BMI over 30kg/m2 or 27 kg/m2 with an obesity-related comorbidity. The interest in EBMT is growing given their safety, efficacy, and non-invasive nature. Current FDA-cleared devices that can be used for EBMT include intragastric balloons and suturing devices for endoscopic sleeve gastroplasty (ESG). Additionally, a variety of Endo surgical knifes are approved for tissue dissection such as myotomy.
Gastric interventions used to treat obesity work by interfering with gastric accommodation, breakdown and mixing of food, or gastric emptying. Delaying gastric emptying was shown to be a major mechanism of action for both ESG and IGB which is also correlated with weight loss [6].
Antral peristalsis constitutes an important mechanism for gastric emptying. The antrum also serves as a food sensor which needs to be filled to a certain level before food is pumped into the duodenum. [7] Therefore, targeting the antrum is a feasible strategy to delay gastric emptying, induce satiety, and promote weight loss.
In fact, one of the recently FDA-cleared EBMT devices, the Transpyloric Shuttle (Baronova, MA), focuses on inhibiting the antral pump as its primary mechanism of action. This device consists of two interconnected large and small bulbs, positioned in the antrum and duodenum respectively, that cause intermittent obstruction of the pylorus, leading to a delay in gastric emptying (10).
As such, a pylorus sparing antral myotomy (PSAM) with a submucosal tunneling technique was developed. Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The PSAM technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events.
Traditional bariatric surgery is very effective at treating obesity, however, only 1% of eligible patients elect to undergo this treatment option. Additionally, the majority of patients with obesity do not qualify for bariatric surgery. [5] Due to the less invasive nature of PSAM, and relative technical simplicity compared to ESG) this procedure may provide a more widely available and more acceptable treatment option for some patients.
There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
This study's planned enrollment of 30 is below the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Browse Obesity, Morbid studies →Christopher C. Thompson, MD, MSc is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adults in the Center for Weight Management and Wellness program at Brigham and Women's Hospital with a BMI >35 kg/m2 who are pre-qualified by their insurance as recommended by their specialist to undergo an endoscopic bariatric procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with no prior endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
Procedure: PSAM Treatment Patients
Subjects with prior primary endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
Procedure: PSAM Treatment Patients
Subjects with prior revision endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.
Procedure: PSAM Treatment Patients
PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
Also known as: PSAM
Weight change compared to baseline
Percent total body weight loss
Time frame: Screening, Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months
Adverse Events
Changes to health compared to baseline
Time frame: Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months
Change in tolerability from procedure day to 12 months
How the subjects feel after the procedure based on pain scale and AE's
Time frame: Procedure day, 1 month, 3 month, 6 month, 9 month, 12 months
Change in Quality of Life compared to baseline
Overall quality of life questionnaire
Time frame: Screening, 1 month, 3 month, 6 month, 9 month, 12 months
Gastric Emptying compared to baseline
Gastric emptying using a gastric emptying breath test (GEBT)
Time frame: Screening, 6 months, 12 months
Ghrelin levels compared to baseline
Laboratory analysis of blood samples to test ghrelin levels
Time frame: Screening, 6 months, 12 months
Insulin levels compared to baseline
Laboratory analysis of blood samples to test insulin metabolic profiles
Time frame: Screening, 6 months, 12 months
HgA1c levels compared to baseline
Laboratory analysis of blood samples to test HgA1c metabolic profiles
Time frame: Screening, 6 months, 12 months
Glucose levels compared to baseline
Laboratory analysis of blood samples to test Glucose metabolic profiles
Time frame: Screening, 6 months, 12 months
HOMA-IR blood plasma levels compared to baseline
Laboratory analysis of blood samples to test changes in insulin resistance
Time frame: Screening, 6 months, 12 months
Physiologic Changes of gastric motility/transit compared to baseline
Upper GI series comparing pre-procedure barium transit to post-procedure 6 and 12 month time points.
Time frame: Screening, 6 months, 12 months
Gastric Motility compared to baseline
Dynamic MRI
Time frame: Screening, 1 month
Plan to share: No — As this is a pilot study to collect data for a larger NIH grant submission, we do not have plans to share data at this time.
Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.
Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 39 months is below that.
Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Christopher C. Thompson, MD, MSc